Methods of using anti-egf antibodies to augment the activity of braf and kras inhibitors
AssigneeIn3Bio Ltd.
InventorsErik D'Hondt, Miguel Angel Molina-Vila
Life of this patent
Estimating the term…
Abstract
Embodiments of the present disclosure are directed to methods for treating and preventing disease conditions, such as cancer, particularly in those individuals who have developed a resistance to, or who are not responsive to, cancer therapies involving v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) or Kirsten rat sarcoma oncogene homolog (KRAS) inhibitors.
Claims17
Use of an active immunization targeting Epidermal Growth Factor (EGF) comprising an immunogenic polypeptide including an EGF, or portions thereof, and a BRAF inhibitor or a KRAS inhibitor, characterized in that the use is for the manufacture of a medicament or a composition for treating colorectal cancer (CRC) in a patient,
- wherein the BRAF inhibitor is administered according to a continuous regimen based on an average daily dose in the range of 10 mg to 150 mg and the active immunization is co-administered according to a therapeutically effective amount repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least once monthly,
- wherein said medicament or composition causes an immune response to EGF for inhibition of the metabolic pathway activated by EGF-EGFR.
Use of a BRAF inhibitor and a monoclonal anti-Epidermal Growth Factor (EGF) antibody, characterized in that the use is for the manufacture of a medicament or a composition for treating colorectal cancer (CRC) in a patient.
The use according to claim 7, wherein the BRAF inhibitor is selected from the group consisting of vemurafenib, dabrafenib, encorafenib, and pharmaceutically acceptable salts thereof.
A therapeutic composition for reducing resistance to BRAF inhibitors characterized by comprising an immunogenic polynucleotide having the sequence selected from the group consisting of SEQ ID NO:
- 1 and SEQ ID NO:
- 2, optionally including an adjuvant or pharmaceutical excipients.
A pharmaceutical kit, characterized by comprising:
- (i) a first compartment which comprises an effective amount of an anti-Epidermal Growth Factor (EGF) target antibodies and a second compartment which comprises an effective amount of a BRAF inhibitor);
- or
- (ii) a first compartment which comprises an effective amount of a vaccine producing an immune response to EGF and a second compartment which comprises an effective amount of a BRAF inhibitor;
- or
- (iii) a first compartment which comprises an effective amount of a vaccine producing an immune response to EGFR and a second compartment which comprises an effective amount of a BRAF inhibitor.
Use of a BRAF inhibitor, characterized in that the use is for preparation of a pharmaceutical kit for treatment of colorectal cancers in a patient in need thereof, wherein the kit comprises a first compartment which comprises an effective amount of a vaccine producing an immune response to EGF and a second compartment which comprises an effective amount of a BRAF inhibitor.
Dependencies are inferred from the claim text.